2012 China Outlook: China’s Year Of The Dragon Will See Continued Growth Grounded By Healthcare Reform Stabilization
This article was originally published in PharmAsia News
As China gets ready to celebrate the Lunar New Year, the Year of the Dragon will see continued growth for the pharmaceutical industry despite several policy headwinds.
You may also be interested in...
SHANGHAI - China's prescription drugs market has seen a slowdown in growth in large cities due to implementation of government pilot reimbursement projects that could be adopted nationwide, according to a Sept. 27 Citi report
Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 2 of 2)
Sanofi SA China Pharmaceutical Operations General Manager Fabrice Baschiera spent more than eight years in Asia working for Sanofi's Asia operations in South Korea, Thailand and Vietnam before he moved to China last August.
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts